title: Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).
abstract: Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.
authors.affiliation: Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
authors.forename: E J
authors.initials: EJ
authors.lastname: Davidson
authors.forename: R L
authors.initials: RL
authors.lastname: Faulkner
authors.forename: P
authors.initials: P
authors.lastname: Sehr
authors.forename: M
authors.initials: M
authors.lastname: Pawlita
authors.forename: L J C
authors.initials: LJ
authors.lastname: Smyth
authors.forename: D J
authors.initials: DJ
authors.lastname: Burt
authors.forename: A E
authors.initials: AE
authors.lastname: Tomlinson
authors.forename: J
authors.initials: J
authors.lastname: Hickling
authors.forename: H C
authors.initials: HC
authors.lastname: Kitchener
authors.forename: P L
authors.initials: PL
authors.lastname: Stern
mesh_terms: D000328:Adult; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology*; D002455:Cell Division; D004279:DNA, Viral / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005982:Glutathione Transferase / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis; D007371:Interferon-gamma / Q000378:metabolism; D027383:Papillomaviridae / Q000276:immunology*; D010835:Phytohemagglutinins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D014616:Vaccinia virus / Q000276:immunology*; D014844:Vulva / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000473:pathology
chemical_list: D019496:Cancer Vaccines; D004279:DNA, Viral; D007074:Immunoglobulin G; D010835:Phytohemagglutinins; D007371:Interferon-gamma; D005982:Glutathione Transferase